Middle East Pharmaceutical Industries Company “Avalon Pharma” announces the approval of the Saudi Food and Drug Authority (SFDA) to register new production lines at the company's Factory No. 2 in Riyadh

Middle East Pharmaceutical Industries Company "Avalon Pharma" is pleased to announce the approval of the Saudi Food and Drug Authority (SFDA) for the registration of new production lines at the company's Plant No. (2) in Riyadh city.

 

The newly approved production lines include lines for capsules and tablets, as well as semi-solids, including creams, ointments, and gels. When fully operational, the newly registered lines will have a production capacity of 270 million tablets and capsules per year, while semi-solids will have a production capacity of 22 million units per year.

 

Commercial production will commence on the new production lines upon obtaining the necessary approvals from the Saudi Food and Drug Authority (SFDA) relevant to the targeted products.

 

For more information, please contact the company's Investor Relations Department at investors.relations@avalon.com.sa